STOCKHOLM – Elekta’s (EKTA-B.ST) Nomination Committee for the Annual General Meeting 2026 has been appointed in accordance with the instructions for the Nomination Committee adopted by the Annual General Meeting 2024.
The Nomination Committee consists of:
The Nomination Committee will appoint one of its members as Chairman.
Shareholders wishing to submit proposals to Elekta’s Nomination Committee can do so by e-mail to peter.nyquist@elekta.com or by letter to:
Elekta AB (publ)
Att: Nomination Committee
P.O. Box 7593
SE-103 93 Stockholm
Sweden
In order for the Nomination Committee to be able to process any proposals constructively, these should be received by the Nomination Committee no later than June 5, 2026.
# # #
For further information, please contact:
Peter Nyquist, Vice President Investor Relations
Tel: +46 70 424 6127, e-mail: peter.nyquist@elekta.com
Time zone: CET: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.